

+

CP 1651 #24
PTO/SB/08A (10-96)
10/31/99. OMB 0651-0031
DEPARTMENT OF COMMERCE
a valid OMB control number.

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449. VPTO

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/444,144
Filing Date	11-20-99
First Named Inventor	Howell, Mark D.
Group Art Unit	1651
Examiner Name	
Attorney Docket Number	Cvto001

U.S. PATENT DOCUMENTS

[illegible]

MAR 10 2000

TECH CENTER 1800/2900

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

7/20/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/088 (10-96)


Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/444,144
		Filing Date	11-20-99
		First Named Inventor	Howell, Mark D.
		Group Art Unit	1651
		Examiner Name	
Sheet 1 of 1	Attorney Docket Number	Cyto001	

ATTACH
TO
#4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
LEK	1	ADERKA, D., et al., "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients", <u>Cancer Research</u> , vol. 51, pp. 5602-5607 (1991).	
LEK	2	ELSASSER-BEILE, U., et al., "Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients", <u>Tumor Biology</u> , vol. 15, pp. 17-24 (1994).	
LEK	3	DIGEL, W., et al., "High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia", <u>Journal of Clinical Investigation</u> , vol. 89, pp. 1690-1693 (1992).	
LEK	4	LENTZ, M. R., "Continuous whole blood ultrapheresis procedure in patients with metastatic cancer", <u>Journal of Biological Response Modifiers</u> , vol. 8, pp. 511-527 (1989).	
LEK	5	LENTZ, M. R., "The role of therapeutic apheresis in the treatment of cancer: a review", <u>Therapeutic Apheresis</u> , vol. 3, pp. 40-49 (1999).	
LEK	6	LENTZ, R., et al., "Low molecular weight protein apheresis and regression of breast cancer", <u>Japanese Journal of Apheresis</u> , vol. 16, pp. 107-114 (1997).	
LEK	7	KESSLER, S. B., "Adsorptive plasma treatment: optimization of extracorporeal devices and systems", <u>Blood Purification</u> , vol. 11, pp. 150-157 (1993).	
LEK	8	SELINSKY, C. L., et al., "Multifaceted inhibition of anti-tumor immune mechanisms by soluble tumour necrosis factor receptor type I", <u>Immunology</u> , vol. 94, pp. 88-93 (1998).	
LEK	9	SELINSKY, C. L. and HOWELL, M. D., "Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo", <u>Cellular Immunology</u> , in press (2000).	

Examiner Signature		Date Considered	7/20/00
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.